Pavurutamab

Tax included
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).
HY-P99814

Data sheet

Size
Multiple sizes
Reactivity
CD3
Application
COVID-19-immunoregulation
CAS
2250292-39-6